BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Trade (domestic/foreign) TRD
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Health Issues HCR
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. H.R. 878, Right to Try Act of 2017 and S. 204, Trickett Wendler Right to Try Act of 2017,lobbied regarding all biopharmaceutical provisions. Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, lobbied regarding all biopharmaceutical provisions. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. HR 2430,FDA Reauthorization Act, lobbied regarding all biopharmaceutical provisions. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R.1231 and S. 456, RACE for Children Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. No bill, Children's Health Insurance Program, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Budget/Appropriations BUD
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.